One HPV Vaccine Dose Protective Against Cervical Cancer?
According to the CDC, the human papillomavirus (HPV) infection causes an estimated nearly 35,000 cases of cancer in women and men annually in the United States, and HPV vaccination could prevent more than 90% of cancers caused by HPV. The CDC recommends that all individuals aged 11 to 12 years receive two doses of HPV vaccine to protect against infections that cause six types of cancer. Results from a new study, however, suggest that one dose of the HPV vaccine may be effective against cervical cancer. Read more. 

Targeted Treatments Might Prolong Pancreatic-Cancer Survival
The American Cancer Society (ACS) reports that pancreatic cancer accounts for 3% of all cancers and 7% of all cancer deaths. The ACS also reveals that for all stages of pancreatic cancer combined, the 1-year relative survival rate is 20% and the 5-year rate is 7%. A recent publication explored the effects of therapies that target a mutation protein when administered to patients with pancreatic cancer. Results from the recent study indicate that the use of targeted therapies may improve survival rates in patients with pancreatic cancer. Read more.

FDA Accepts BLA for HER2 Breast Cancer Combination Treatment
Human epidermal growth factor receptor 2 (HER2) is a gene that plays a role in the development of breast cancer. The American Society of Clinical Oncology/College of American Pathologists reports that an estimated 15% to 20% of breast-cancer cases are HER2-positive based on diagnostic test results. On February 25, 2020, the FDA accepted the biologics license application for a fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer, with an approval decision expected by October 18, 2020. Read more.